New approaches for preventing and treating chronic graft-versus-host disease - PubMed (original) (raw)

Review

New approaches for preventing and treating chronic graft-versus-host disease

Stephanie J Lee. Blood. 2005.

Abstract

Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation (HCT) over the last 25 years, chronic graft-versus-host disease (GVHD) remains a substantial problem with little change in the incidence, morbidity, and mortality of this complication. In fact, with increased use of peripheral blood, transplantation of older patients, and less immediate transplantation-related mortality, the prevalence of chronic GVHD may increase. One of the difficulties in combating chronic GVHD is a lack of understanding about the pathophysiology of the syndrome. Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD.

PubMed Disclaimer

Similar articles

• Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
  Bryant A, Mallick R, Huebsch L, Allan D, Atkins H, Anstee G, Sabloff M, Scrivens N, Maze D, Bredeson C, Kekre N. Bryant A, et al. Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15. Biol Blood Marrow Transplant. 2017. PMID: 28821454
• Graft-versus-host disease management.
  Mistrik M, Bojtarova E, Sopko L, Masakova L, Roziakova L, Martinka J, Batorova A. Mistrik M, et al. Bratisl Lek Listy. 2016;117(7):388-96. doi: 10.4149/bll_2016_077. Bratisl Lek Listy. 2016. PMID: 27546540
• Are we making progress in GVHD prophylaxis and treatment?
  Pavletic SZ, Fowler DH. Pavletic SZ, et al. Hematology Am Soc Hematol Educ Program. 2012;2012:251-64. doi: 10.1182/asheducation-2012.1.251. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233589 Review.
• Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
  Kumari R, Palaniyandi S, Hildebrandt GC. Kumari R, et al. Dig Dis Sci. 2019 Mar;64(3):669-677. doi: 10.1007/s10620-018-5369-9. Epub 2018 Dec 7. Dig Dis Sci. 2019. PMID: 30523482 Review.
• Chronic graft-versus-host disease: is there an alternative to the conventional treatment?
  Gaziev D, Galimberti M, Lucarelli G, Polchi P. Gaziev D, et al. Bone Marrow Transplant. 2000 Apr;25(7):689-96. doi: 10.1038/sj.bmt.1702235. Bone Marrow Transplant. 2000. PMID: 10745252 Review.

Cited by

• Targeting PRMT1 prevents acute and chronic graft-versus-host disease.
  Zhao X, Sun Y, Xu Z, Cai L, Hu Y, Wang H. Zhao X, et al. Mol Ther. 2023 Nov 1;31(11):3259-3276. doi: 10.1016/j.ymthe.2023.09.011. Epub 2023 Sep 20. Mol Ther. 2023. PMID: 37735873 Free PMC article.
• Perspectives on oral chronic graft-versus-host disease from immunobiology to morbid diagnoses.
  Tollemar V, Garming Legert K, Sugars RV. Tollemar V, et al. Front Immunol. 2023 Jun 28;14:1151493. doi: 10.3389/fimmu.2023.1151493. eCollection 2023. Front Immunol. 2023. PMID: 37449200 Free PMC article. Review.
• A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.
  Ong JCM, Than H, Tripathi S, Gkitzia C, Wang X. Ong JCM, et al. Cost Eff Resour Alloc. 2023 May 31;21(1):34. doi: 10.1186/s12962-023-00444-w. Cost Eff Resour Alloc. 2023. PMID: 37259074 Free PMC article.
• Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation.
  Zhang J, Wang X, Wang R, Chen G, Wang J, Feng J, Li Y, Yu Z, Xiao H. Zhang J, et al. Biomedicines. 2023 Mar 20;11(3):949. doi: 10.3390/biomedicines11030949. Biomedicines. 2023. PMID: 36979928 Free PMC article.
• A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
  Soder RP, Dawn B, Weiss ML, Dunavin N, Weir S, Mitchell J, Li M, Shune L, Singh AK, Ganguly S, Morrison M, Abdelhakim H, Godwin AK, Abhyankar S, McGuirk J. Soder RP, et al. Stem Cell Rev Rep. 2020 Oct;16(5):979-991. doi: 10.1007/s12015-020-10015-8. Stem Cell Rev Rep. 2020. PMID: 32740891 Free PMC article. Clinical Trial.

References

1. 1. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100: 415-419. - PubMed
2. 1. Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;100: 1192-1200. - PubMed
3. 1. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341: 14-21. - PubMed
4. 1. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100: 406-414. - PubMed
5. 1. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336: 897-904. - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database